- Home
- PLSE vs INBX Comparison
PLSE vs INBX Comparison
Compare PLSE & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLSE | INBX |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2015 | 2024 |
Fundamental Metrics
Financial Performance| Metric | PLSE | INBX |
|---|---|---|
| Price | $24.09 | $97.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $22.00 | ★ $150.00 |
| AVG Volume (30 Days) | 362.2K | ★ 440.2K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $840.00 | N/A |
| Revenue Next Year | $287.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $12.56 | $12.80 |
| 52 Week High | $27.98 | $155.29 |
Technical Indicators
Market Signals| Indicator | PLSE | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 42.09 |
| Support Level | $17.58 | $69.30 |
| Resistance Level | $27.14 | $153.14 |
| Average True Range (ATR) | 1.89 | 10.51 |
| MACD | -0.02 | -3.18 |
| Stochastic Oscillator | 49.24 | 2.50 |
Price Performance
Historical ComparisonAbout PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.